Skip to main content

Advertisement

SpringerLink
Log in

The European Treatment and Outcome Study score is associated with clinical outcomes and treatment response following European LeukemiaNet 2013 recommendations in chronic-phase chronic myeloid leukemia

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

The introduction of tyrosine kinase inhibitors has dramatically improved outcomes for many patients with chronic myeloid leukemia (CML), but some cases are resistant to this treatment. To compare the prognostic performance of Sokal, Hasford, and European Treatment and Outcome Study (EUTOS) scores, patient outcomes and treatment responses were investigated following the European LeukemiaNet (ELN) 2013 recommendations. Seventy-three patients with newly diagnosed chronic-phase CML (CML-CP) treated with any tyrosine kinase inhibitor as initial therapy were analyzed. All scoring systems significantly predicted treatment response at 3 and 6 months; however, only the EUTOS score significantly predicted treatment response at 12 months, following the ELN 2013 recommendations. The 5-year event-free survival rates were 93 and 35 % in the low- and high-risk groups according to the EUTOS score (P < 0.0001). Moreover, the 5-year overall survival rates were 98 and 51 % in the low- and high-risk groups by EUTOS score (P < 0.0001). We suggest that the EUTOS score may provide a better stratification of CML-CP patients for predicting treatment response.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994–1004.

    Article  PubMed  Google Scholar 

  2. Kantarjian H, O’Brien S, Jabbour E, Shan J, Ravandi F, Kadia T, et al. Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia. J Clin Oncol. 2011;29:3173–8.

    Article  PubMed  Google Scholar 

  3. Tauchi T, Kizaki M, Okamoto S, Tanaka H, Tanimoto M, Inokuchi K, et al. Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system. Leuk Res. 2011;35:585–90.

    Article  PubMed  CAS  Google Scholar 

  4. Kim D, Goh HG, Kim SH, Choi SY, Park SH, Jang EJ, et al. Comprehensive therapeutic outcomes of frontline imatinib mesylate in newly diagnosed chronic phase chronic myeloid leukemia patients in Korea: feasibility assessment of current ELN recommendation. Int J Hematol. 2012;96:47–57.

    Article  PubMed  CAS  Google Scholar 

  5. Mitra D, Trask PC, Iyer S, Candrilli SD, Kaye JA. Patient characteristics and treatment patterns in chronic myeloid leukemia: evidence from a multi-country retrospective medical record chart review study. Int J Hematol. 2012;95:263–73.

    Article  PubMed  CAS  Google Scholar 

  6. Trask PC, Mitra D, Iyer S, Candrilli SD, Kaye JA. Patterns and prognostic indicators of response to CML treatment in a multi-country medical record review study. Int J Hematol. 2012;95:535–44.

    Article  PubMed  Google Scholar 

  7. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251–9.

    Article  PubMed  CAS  Google Scholar 

  8. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362:2260–70.

    Article  PubMed  CAS  Google Scholar 

  9. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, et al. Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood. 1984;63:789–99.

    PubMed  CAS  Google Scholar 

  10. Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst. 1998;90:850–8.

    Article  PubMed  CAS  Google Scholar 

  11. Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood. 2011;118:686–92.

    Article  PubMed  CAS  Google Scholar 

  12. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872–84.

    Article  PubMed  CAS  Google Scholar 

  13. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27:6041–51.

    Article  PubMed  CAS  Google Scholar 

  14. Langabeer SE, Gale RE, Harvey RC, Cook RW, Mackinnon S, Linch DC. Transcription-mediated amplification and hybridisation protection assay to determine BCR-ABL transcript levels in patients with chronic myeloid leukaemia. Leukemia. 2002;16:393–9.

    Article  PubMed  CAS  Google Scholar 

  15. Ohnishi K, Nakaseko C, Takeuchi J, Fujisawa S, Nagai T, Yamazaki H, et al. Long-term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: the JALSG CML202 study. Cancer Sci. 2012;103:1071–8.

    Article  PubMed  CAS  Google Scholar 

  16. Yamamoto E, Fujisawa S, Hagihara M, Tanaka M, Fujimaki K, Kishimoto K, et al. European treatment and outcome study score does not predict imatinib treatment response and outcome in chronic myeloid leukemia patients. Cancer Sci. 2014;105:105–9.

    Article  PubMed  CAS  Google Scholar 

  17. Jabbour E, Cortes J, Nazha A, O’Brien S, Quintas-Cardama A, Pierce S, et al. EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience. Blood. 2012;119:4524–6.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  18. Hoffmann VS, Baccarani M, Lindoerfer D, Castagnetti F, Turkina A, Zaritsky A, et al. The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib. Leukemia. 2013;27:2016–22.

    Article  PubMed  CAS  Google Scholar 

  19. Tiribelli M, Bonifacio M, Calistri E, Binotto G, Maino E, Marin L, et al. EUTOS score predicts long-term outcome but not optimal response to imatinib in patients with chronic myeloid leukaemia. Leuk Res. 2013;37:1457–60.

    Article  PubMed  CAS  Google Scholar 

  20. Bonifacio M, Binotto G, Calistri E, Maino E, Tiribelli M. Gruppo Triveneto LMC. EUTOS score predicts early optimal response to imatinib according to the revised 2013 ELN recommendations. Ann Hematol. 2014;93:163–4.

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

M.T. Received research grants from Bristol and Novartis. N.I. And Y.H. received honoraria from Bristol and Novartis. The other authors declare no competing financial interests.

Author information

Authors and Affiliations

  1. Department of Hematology and Rheumatology, Nihon University School of Medicine, 30-1 Oyaguchi Kami-cho, Itabashi-ku, Tokyo, 173-8610, Japan

    Noriyoshi Iriyama, Yoshihiro Hatta, Sumiko Kobayashi, Yoshihito Uchino, Katsuhiro Miura, Daisuke Kurita, Hitomi Kodaira & Masami Takei

  2. Department of Clinical Laboratory, Nihon University School of Medicine, 30-1 Oyaguchi Kami-cho, Itabashi-ku, Tokyo, 173-8610, Japan

    Mitsuru Inoue

Authors
  1. Noriyoshi Iriyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoshihiro Hatta
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sumiko Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yoshihito Uchino
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Katsuhiro Miura
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Daisuke Kurita
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hitomi Kodaira
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Mitsuru Inoue
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Masami Takei
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Noriyoshi Iriyama or Yoshihiro Hatta.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Iriyama, N., Hatta, Y., Kobayashi, S. et al. The European Treatment and Outcome Study score is associated with clinical outcomes and treatment response following European LeukemiaNet 2013 recommendations in chronic-phase chronic myeloid leukemia. Int J Hematol 100, 379–385 (2014). https://doi.org/10.1007/s12185-014-1649-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-014-1649-0

Keywords

Search

Navigation